Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: T(8;21) and inv(16) represent different clinical outcomes

Yachiyo Kuwatsuka, Koichi Miyamura, Ritsuro Suzuki, Masaharu Kasai, Atsuo Maruta, Hiroyasu Ogawa, Ryuji Tanosaki, Satoshi Takahashi, Kyuhei Koda, Kazuhiro Yago, Yoshiko Atsuta, Takashi Yoshida, Hisashi Sakamaki, Yoshihisa Kodera

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

We analyzed 338 adult patients with acute myeloid leukemia (AML) with t(8;21) and inv(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society for Hematopoietic Cell Transplantation database. At 3 years, overall survival (OS) of patients with t(8;21) and inv(16) was 50% and 72%, respectively (P = .002). Although no difference was observed when restricted to allogeneic SCT in first complete remission (CR; 84% and 74%), OS of patients with t(8;21) and inv(16) undergoing allogeneic SCT in second or third CR (45% and 86% at 3 years; P = .008) was different. OS was not different between patients in first CR who received allogeneic SCT and those who received autologous SCT for both t(8;21) AML (84% vs 77%; P= .49) and inv(16) AML (74% vs 59%; P= .86). Patients with inv(16) not in CR did better after allogeneic SCT than those with t(8;21) (70% and 18%; P= .03). Patients with t(8;21) and inv(16) should be managed differently as to the application of SCT. SCT in first CR is not necessarily recommended for inv(16). For t(8;21) patients in first CR, a prospective trial is needed to clarify the significance of autologous SCT and allogeneic SCT over chemotherapy.

Original languageEnglish
Pages (from-to)2096-2103
Number of pages8
JournalBlood
Volume113
Issue number9
DOIs
Publication statusPublished - 2009 Feb 26
Externally publishedYes

Fingerprint

Core Binding Factors
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Stem cells
Acute Myeloid Leukemia
Survival
Chemotherapy
Cell Transplantation
Japan

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia : T(8;21) and inv(16) represent different clinical outcomes. / Kuwatsuka, Yachiyo; Miyamura, Koichi; Suzuki, Ritsuro; Kasai, Masaharu; Maruta, Atsuo; Ogawa, Hiroyasu; Tanosaki, Ryuji; Takahashi, Satoshi; Koda, Kyuhei; Yago, Kazuhiro; Atsuta, Yoshiko; Yoshida, Takashi; Sakamaki, Hisashi; Kodera, Yoshihisa.

In: Blood, Vol. 113, No. 9, 26.02.2009, p. 2096-2103.

Research output: Contribution to journalArticle

Kuwatsuka, Y, Miyamura, K, Suzuki, R, Kasai, M, Maruta, A, Ogawa, H, Tanosaki, R, Takahashi, S, Koda, K, Yago, K, Atsuta, Y, Yoshida, T, Sakamaki, H & Kodera, Y 2009, 'Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: T(8;21) and inv(16) represent different clinical outcomes', Blood, vol. 113, no. 9, pp. 2096-2103. https://doi.org/10.1182/blood-2008-03-145862
Kuwatsuka, Yachiyo ; Miyamura, Koichi ; Suzuki, Ritsuro ; Kasai, Masaharu ; Maruta, Atsuo ; Ogawa, Hiroyasu ; Tanosaki, Ryuji ; Takahashi, Satoshi ; Koda, Kyuhei ; Yago, Kazuhiro ; Atsuta, Yoshiko ; Yoshida, Takashi ; Sakamaki, Hisashi ; Kodera, Yoshihisa. / Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia : T(8;21) and inv(16) represent different clinical outcomes. In: Blood. 2009 ; Vol. 113, No. 9. pp. 2096-2103.
@article{1b1b95de4ec7459e9f36e0170988ab71,
title = "Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: T(8;21) and inv(16) represent different clinical outcomes",
abstract = "We analyzed 338 adult patients with acute myeloid leukemia (AML) with t(8;21) and inv(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society for Hematopoietic Cell Transplantation database. At 3 years, overall survival (OS) of patients with t(8;21) and inv(16) was 50{\%} and 72{\%}, respectively (P = .002). Although no difference was observed when restricted to allogeneic SCT in first complete remission (CR; 84{\%} and 74{\%}), OS of patients with t(8;21) and inv(16) undergoing allogeneic SCT in second or third CR (45{\%} and 86{\%} at 3 years; P = .008) was different. OS was not different between patients in first CR who received allogeneic SCT and those who received autologous SCT for both t(8;21) AML (84{\%} vs 77{\%}; P= .49) and inv(16) AML (74{\%} vs 59{\%}; P= .86). Patients with inv(16) not in CR did better after allogeneic SCT than those with t(8;21) (70{\%} and 18{\%}; P= .03). Patients with t(8;21) and inv(16) should be managed differently as to the application of SCT. SCT in first CR is not necessarily recommended for inv(16). For t(8;21) patients in first CR, a prospective trial is needed to clarify the significance of autologous SCT and allogeneic SCT over chemotherapy.",
author = "Yachiyo Kuwatsuka and Koichi Miyamura and Ritsuro Suzuki and Masaharu Kasai and Atsuo Maruta and Hiroyasu Ogawa and Ryuji Tanosaki and Satoshi Takahashi and Kyuhei Koda and Kazuhiro Yago and Yoshiko Atsuta and Takashi Yoshida and Hisashi Sakamaki and Yoshihisa Kodera",
year = "2009",
month = "2",
day = "26",
doi = "10.1182/blood-2008-03-145862",
language = "English",
volume = "113",
pages = "2096--2103",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia

T2 - T(8;21) and inv(16) represent different clinical outcomes

AU - Kuwatsuka, Yachiyo

AU - Miyamura, Koichi

AU - Suzuki, Ritsuro

AU - Kasai, Masaharu

AU - Maruta, Atsuo

AU - Ogawa, Hiroyasu

AU - Tanosaki, Ryuji

AU - Takahashi, Satoshi

AU - Koda, Kyuhei

AU - Yago, Kazuhiro

AU - Atsuta, Yoshiko

AU - Yoshida, Takashi

AU - Sakamaki, Hisashi

AU - Kodera, Yoshihisa

PY - 2009/2/26

Y1 - 2009/2/26

N2 - We analyzed 338 adult patients with acute myeloid leukemia (AML) with t(8;21) and inv(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society for Hematopoietic Cell Transplantation database. At 3 years, overall survival (OS) of patients with t(8;21) and inv(16) was 50% and 72%, respectively (P = .002). Although no difference was observed when restricted to allogeneic SCT in first complete remission (CR; 84% and 74%), OS of patients with t(8;21) and inv(16) undergoing allogeneic SCT in second or third CR (45% and 86% at 3 years; P = .008) was different. OS was not different between patients in first CR who received allogeneic SCT and those who received autologous SCT for both t(8;21) AML (84% vs 77%; P= .49) and inv(16) AML (74% vs 59%; P= .86). Patients with inv(16) not in CR did better after allogeneic SCT than those with t(8;21) (70% and 18%; P= .03). Patients with t(8;21) and inv(16) should be managed differently as to the application of SCT. SCT in first CR is not necessarily recommended for inv(16). For t(8;21) patients in first CR, a prospective trial is needed to clarify the significance of autologous SCT and allogeneic SCT over chemotherapy.

AB - We analyzed 338 adult patients with acute myeloid leukemia (AML) with t(8;21) and inv(16) undergoing stem cell transplantation (SCT) who were registered in the Japan Society for Hematopoietic Cell Transplantation database. At 3 years, overall survival (OS) of patients with t(8;21) and inv(16) was 50% and 72%, respectively (P = .002). Although no difference was observed when restricted to allogeneic SCT in first complete remission (CR; 84% and 74%), OS of patients with t(8;21) and inv(16) undergoing allogeneic SCT in second or third CR (45% and 86% at 3 years; P = .008) was different. OS was not different between patients in first CR who received allogeneic SCT and those who received autologous SCT for both t(8;21) AML (84% vs 77%; P= .49) and inv(16) AML (74% vs 59%; P= .86). Patients with inv(16) not in CR did better after allogeneic SCT than those with t(8;21) (70% and 18%; P= .03). Patients with t(8;21) and inv(16) should be managed differently as to the application of SCT. SCT in first CR is not necessarily recommended for inv(16). For t(8;21) patients in first CR, a prospective trial is needed to clarify the significance of autologous SCT and allogeneic SCT over chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=61849159227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61849159227&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-03-145862

DO - 10.1182/blood-2008-03-145862

M3 - Article

C2 - 19126873

AN - SCOPUS:61849159227

VL - 113

SP - 2096

EP - 2103

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -